Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

MD Buyline's User Satisfaction Report Awards MGC Diagnostics Pulmonary Function Products Top Rating for Fourth Consecutive



    MD Buyline's User Satisfaction Report Awards MGC Diagnostics Pulmonary
         Function Products Top Rating for Fourth Consecutive Quarter

Service and support capabilities continue to outperform industry competitors

PR Newswire

SAINT PAUL, Minn., March 4, 2013

SAINT PAUL, Minn., March 4, 2013 /PRNewswire/ -- MGC Diagnostics Corporation
(NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology
company, today announced that its pulmonary function products, service and
support continues to outperform industry competitors as well as increasing its
margin above Market Average. As published in MD Buyline's User Satisfaction
Report^™, MGC Diagnostics has earned the top rating in all categories for its
fourth consecutive quarter. Ratings based on user satisfaction ranks MGC
Diagnostics system performance, system reliability,
installation/implementation, applications training, service response time and
service repair quality singularly higher compared to other vendors in this
space.

(Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO)

Gregg O. Lehman, Ph.D., Chief Executive Officer and President of MGC
Diagnostics, commented, "We are pleased to be recognized by our customers in
the report from MD Buyline for consistently providing unmatched service and
support, relentlessly making improvements and anticipating and solving unmet
needs. These core commitments guide our strategy and define our commitment to
customers, employees and shareholders making us uniquely qualified to solve
today's challenges and uncover solutions for tomorrow's opportunities."

About MD Buyline – MD Buyline, the leading provider of healthcare technology
and clinical research for reducing the purchasing costs across the healthcare
supply chain, provides over 3,000 healthcare providers with unbiased,
up-to-the-minute data on vendors, products, services, and user satisfaction
ratings to ensure they invest in the right technology and services at the
right price. www.mdbuyline.com

About MGC Diagnostics

MGC Diagnostics Corporation, (formerly Angeion Corporation) through its
subsidiary Medical Graphics Corporation, is a global medical technology
company dedicated to cardiorespiratory health solutions. MGC Diagnostics
develops, manufactures and markets non-invasive diagnostic systems. This
portfolio of products provides solutions for disease detection, integrated
care, and wellness across the spectrum of cardiorespiratory healthcare. The
Company's products are sold internationally through distributors and in the
United States through a direct sales force targeting heart and lung
specialists located in hospitals, university-based medical centers, medical
clinics, physicians' offices, pharmaceutical companies, medical device
manufacturers, and clinical research organizations (CROs). For more
information about MGC Diagnostics, visit www.mgcdiagnostics.com.

Cautionary Statement Regarding Forward Looking Statements

From time to time, in reports filed with the Securities and Exchange
Commission, in press releases, and in other communications to shareholders or
the investing public, MGC Diagnostics Corporation may make forward−looking
statements concerning possible or anticipated future financial performance,
business activities or plans that include the words "believes," "expects,"
"anticipates," "intends" or similar expressions. For these forward−looking
statements, the Company claims the protection of the safe harbor for
forward−looking statements contained in federal securities laws. These
forward−looking statements are subject to a number of factors, risks and
uncertainties, including those disclosed in our periodic filings with the SEC,
that could cause actual performance, activities or plans after the date the
statements are made to differ significantly from those indicated in the
forward−looking statements. For a list of these factors¸ see the sections
entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking
Statements," in the Company's Form 10-K for the year ended October 31, 2012,
and any updates in subsequent filings on Form 10-Q or Form 8-K under the
Securities Exchange Act of 1934.

Contact:     Gregg O. Lehman, Ph.D.               Joe Dorame, Robert Blum, Joe
                                                  Diaz
             MGC Diagnostics Corporation          Lytham Partners, LLC
             Chief Executive                      (602) 889-9700
             Officer              
             (651) 484-4874                       mgcd@lythampartners.com

 

SOURCE MGC Diagnostics Corporation

Website: http://www.mgcdiagnostics.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement